Curis, Inc.
CRIS
Rank in Stocks
#32638
Curis, Inc., a biotechnology company, engages in the discovery and development... Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The companyโs pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Share Price
$0.6976
Last synced: 2026-11-09
Market Cap
$1.36M
Change (1 day)
-23.04%
Change (1 year)
-97.21%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Curis, Inc. (CRIS)
Category
Healthcare
Operating Margin for Curis, Inc. (CRIS)
Operating Margin as of November 2026 TTM: -833.40%
According to Curis, Inc.'s latest financial reports, its current operating margin (TTM) is -833.40%. At the end of 2025 the company had an operating margin of -348.43%.
Operating Margin history for Curis, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -833.40% | 139.19% |
| 2025 | -348.43% | -14.67% |
| 2024 | -408.34% | -15.32% |
| 2023 | -482.21% | -7.58% |
| 2022 | -521.75% | 32.09% |
| 2021 | -395.01% | 71.90% |
| 2020 | -229.79% | -5.61% |
| 2019 | -243.46% | -13.45% |
| 2018 | -281.29% | -44.05% |
| 2017 | -502.73% | -34.80% |
| 2016 | -771.08% | 7.56% |
| 2015 | -716.91% | 344.90% |
| 2014 | -161.14% | 156.71% |
| 2013 | -62.77% | -42.79% |
| 2012 | -109.71% | 124.86% |
| 2011 | -48.79% | 38.45% |
| 2010 | -35.24% | -69.86% |
| 2009 | -116.94% | -25.43% |
| 2008 | -156.81% | 206.87% |
| 2007 | -51.10% | -24.09% |
| 2006 | -67.32% | -74.53% |
| 2005 | -264.35% | -16.21% |
| 2004 | -315.48% | 251.63% |
| 2003 | -89.72% | -79.22% |
| 2002 | -431.67% | -93.50% |
| 2001 | -6,642.87% | 56.27% |
| 2000 | -4,250.95% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.82% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Curis, Inc.'s operating margin
What is Curis, Inc.'s operating margin?
Curis, Inc.'s operating margin is -833.40%, as of Nov 2026.
What was Curis, Inc.'s operating margin in 2025?
In 2025, Curis, Inc.'s operating margin was -348.43%, compared with -408.34% in 2024.
How has Curis, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Curis, Inc.'s operating margin was highest in 2020 (-229.79%) and lowest in 2022 (-521.75%).
How does Curis, Inc.'s operating margin compare with similar companies?
Curis, Inc.'s operating margin (-833.40%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.